摘要
对含铂类药物治疗后复发的非小细胞肺癌,单药泰索帝为标准的二线化疗药物,可明显延长病人的生存时间及改善生活质量。一项泰索帝的Ⅲ期随机对照研究证实,多靶点叶酸抑制剂的抗代谢药Alimta二线化疗治疗非小细胞肺癌,其疗效、中位生存时间及1年生存率与泰索帝相似,可替代泰索帝成为晚期NSCLC的二线化疗药物。泰索帝与健择、卡铂、伊立替康、EGFR-TK抑制剂及抗血管生成剂联合化疗,有一定的疗效。TXT为复发的NSCLC常用的二线标准治疗方案。Alimta为备用的二线治疗方案。Iressa单药对铂类及泰索帝失败后的晚期非小细胞肺癌仍然有效。
Single agent docetaxel as the standard second line treatment was reported to show promising activity leading to the improved survival and quality of life in NSCLC patients recurring after platinum-based chemotherapy.Pemetrexed disodium,a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway,is simlar to TXT in overall response rate,median survival time and 1 year survival rate in a randomized phase Ⅲ trail of pemetrexed versus docetaxal in patients with NSCLC previously treated with chemptherapy,pemetrexed should be considered a standard treatment option for second line NSCLC.The combination chemotherapy of gemcitabine,carboplatin,CPT-11,gefitinib and thalidomide with docetaxel respectively are active in NSCLC.Single agent docetaxel represents the standard second line treatment in relapsed NSCLC patients.Pemetrexed disodium should be considered a standard treatment option for second-line NSCLC.Iressa as monotherapy after failure of both platinum-based and docetaxel therapies is still active in NSCLC.
出处
《癌症进展》
2005年第3期237-242,共6页
Oncology Progress
关键词
非小细胞肺癌
二线化疗
NSCLC second line(sl) chemotherapy
